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Abstract
Background: Smoking in pregnancy is a public health problem and effective methods for reducing this are required. Although
nicotine replacement therapy (NRT) is effective for smoking cessation in non-pregnant people, there is no direct evidence
concerning its effectiveness in pregnancy. Despite this, clinical guidelines recommend the cautious use of NRT during pregnancy.
Randomised controlled trials are needed to determine the safety and efficacy of NRT when used by pregnant women for
smoking cessation, but the feasibility of recruiting women to such trials is unknown. Consequently, in this study we aimed to
determine i) the feasibility of recruiting women to a RCT of NRT in pregnancy as they attend hospital antenatal ultrasound
examinations, ii) the proportion of such women who are eligible for and interested in trial enrolment and iii) research staff
perceptions of how one method of trial recruitment could be improved.
Methods: During a one month period, all women attending for antenatal ultrasound examination in an English teaching hospital
were asked to complete a questionnaire which determined their eligibility to enrol in a proposed placebo controlled randomised
trial investigating the effectiveness of NRT in pregnancy. Women who were eligible to participate were asked whether they
would do so and those who accepted enrolment were offered an appointment with a smoking cessation advisor.
Results: Over 99% (851/858) of women agreed to complete a questionnaire about smoking habits whilst waiting for ultrasound
examinations. 10.3% (88/851) of women attending for antenatal ultrasound fitted eligibility criteria for a proposed RCT of NRT
in pregnancy, but only 3.6% [(31/851), 95% CI, 2.4 to 4.9%] indicated on the questionnaire that they would like to take part in
a study involving randomisation to placebo or active patches. Researchers offered trial enrolment to 26 of these 31 women and
96% (25) accepted. Staff recruiting women believed that trial recruitment would be maximised if women attending the
ultrasound department knew about trial recruitment before attending and greater staff resources were made available for this.
It was also perceived that women generally under-reported the amount they smoked on questionnaires completed whilst
waiting in ultrasound department areas.
Conclusions: It is feasible to recruit women for a trial of NRT in pregnancy as they wait for antenatal ultrasound examinations.
Using similar recruitment methods, researchers can expect to recruit between 24 and 49 women per 1000 approached.
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Background
Smoking harms unborn children causing intra-uterine
growth restriction, preterm birth, miscarriage and perina-
tal death [1,2]. Despite this over a quarter of pregnant
women in the UK smoke [3] and although pregnancy
motivates a minority of women to stop smoking for at
least part of their pregnancy, most start again after delivery
[3]. Reducing smoking in pregnancy is, therefore, a health
priority and effective methods for promoting smoking
cessation in pregnancy are needed. Behavioural support is
effective for smoking cessation in pregnancy, [4] but drug
treatment is not generally used because of concerns that
this may harm the fetus [5]. Outside of pregnancy, how-
ever, drug therapy can be effective and nicotine replace-
ment therapy (NRT) increases quit rates of smoking
cessation interventions it accompanies by 1.5 to 2-fold
[6]. Unfortunately, the efficacy and safety of NRT in preg-
nancy are unknown.
Two trials conducted in pregnant women have shown
NRT patches to have no greater effect on smoking cessa-
tion than placebo [7,8]. but neither trial has been large
enough to be definitive. Additionally, nicotine is metabo-
lised more quickly in pregnancy [9] and this could reduce
the efficacy of NRT, as conventional doses will provide
less nicotine substitution. Consequently, for NRT to be
effective in pregnancy, higher doses might be needed but
this raises questions of safety because nicotine is a recog-
nised fetal toxin [10] and higher doses could increase the
risk of any fetal damage occurring. Any such risk is diffi-
cult to quantify, though, because there is little human-
subject evidence on the effects of nicotine (or NRT) in
pregnancy and most evidence about the impact of nico-
tine in pregnancy is derived from animal studies [10]. In
humans, nicotine is known to increase maternal blood
pressure and heart rate but to have lesser effects on the
fetal heart rate and these changes are less pronounced
than those caused by smoking [10]. More encouragingly,
the one completed trial of NRT in pregnancy [7] found
babies born to women in the NRT treatment group had
significantly higher birth weight than those treated with
placebo, suggesting that intrauterine growth restriction
caused by smoking is not attributable to nicotine. Further
evidence on the safety of nicotine in pregnancy would
help to inform clinicians' decisions about prescribing NRT
in pregnancy.
Despite uncertainties about the effects of NRT in preg-
nancy, there is an expert consensus that NRT use is safer
than smoking [11] which is reflected in clinical guidelines
[5,12] and other advice to clinicians [13]. NRT use in preg-
nancy is, therefore, being encouraged in the absence of
any direct evidence for it's effectiveness or safety and pla-
cebo-controlled RCTs are needed to resolve these issues.
In pregnancy, women are generally advised to avoid
unnecessary drugs [14] and it is likely, therefore, that
women's reluctance to use drugs (including NRT, which
contains a known fetal toxin [10]) might hinder recruit-
ment to RCTs of NRT in pregnancy. Consequently, this
paper describes a pilot study which aimed to determine: i)
the feasibility of recruiting women to an RCT of NRT in
pregnancy as they attended hospital antenatal ultrasound
examinations, ii) the proportion of pregnant women
attending such clinics who are eligible for enrolment and
interested in participation in such a trial and iii) research
staff perceptions of how one method of recruitment could
be improved for use in a definitive RCT.
Methods
Ethical approval was granted by the Nottingham Research
Ethics Committee 2. For one month, one of three research
assistants (RAs) was based in the Nottingham City Hospi-
tal antenatal ultrasound department for all scanning ses-
sions. All women attending for ultrasound scans were
approached by an RA and asked to fill in a self-completion
questionnaire (see appendix) which asked their number
of weeks gestation and whether or not they smoked at all.
Respondents who answered that they smoked cigarettes or
tobacco were then asked a series of questions about their
smoking behaviour to ascertain whether or not they satis-
fied eligibility criteria for a proposed RCT (see Figure 2).
Those smokers who were at an appropriate gestation, who
smoked heavily enough for entry to the RCT and who
were interested in stopping smoking completed the whole
questionnaire. Before the final questionnaire item, they
read brief information about the use of nicotine replace-
ment therapy in pregnancy (which was on the question-
naire). The final item then asked women whether or not
they would like to take part in a study which investigated
the effectiveness of NRT in pregnancy. Those who did
were subsequently offered enrolment into the study by
the RA and their responses were noted. The enrolment
offer included an explanation that no randomised study
of NRT was currently taking place but that this was possi-
ble in the near future (which, at that time, the authors
believed to be true). Women who agreed to enrolment
were aware that they might participate in a study that
would involve them being randomised to either active or
inactive patches and, although nicotine was potentially
harmful, NRT use was believed to be safer than smoking.
RAs arranged appointments with the local NHS smoking
cessation service [15] for those women who accepted the
offer of enrolment and, if they attended these, women
received counselling from midwives who specialised in
smoking cessation counselling for pregnant women.
Enrolment criteria for the proposed trial (Figure 2) were
constructed to ensure that only women who were
addicted to nicotine were likely to be enrolled in the
study. It was important to prevent any woman fromBMC Health Services Research 2004, 4:29 http://www.biomedcentral.com/1472-6963/4/29
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entering a trial if it were possible that she might receive
more nicotine via NRT dispensed in the trial than she oth-
erwise would have received by smoking [11]. The antena-
tal ultrasound clinic setting was used because almost all
pregnant women in the UK have an ultrasound scan per-
formed between the end of the first and the middle of the
second trimester of pregnancy. By recruiting in this set-
ting, we were able to systematically approach all pregnant
women residing in the local area who were at an appropri-
ate stage of gestation and who were likely to deliver in the
same hospital.
When the pilot was finished, the views of RAs and collab-
orating staff from the local NHS smoking cessation service
were sought at a meeting. We asked their opinions of the
utility of our method for detecting smokers (i.e. the ques-
tionnaire) and the practicality of recruitment within the
ultrasound clinic setting. Where staff had criticisms, they
were encouraged to suggest improvements in procedures.
Key points made during this meeting were noted and
issues described in the results section are those on which
there was consensus.
Sample size and data analysis
We knew from routinely-collected clinic statistics that
over 800 women would attend for antenatal ultrasound
scans in a four week period and around 200 of these
(25%) would smoke. We hypothesised that 20% of smok-
ers (i.e. approximately 40 or 5% of clinic attenders) would
agree to trial randomisation. We believed this a reasona-
ble assumption because in a survey of women attending
ante-natal clinics, Ussher found that, amongst women
who smoked 10 or more cigarettes daily and who were
interested in stopping smoking; 56% were also interested
in using NRT [16]. Consequently, if our survey was con-
ducted for one month, we calculated that would be able
to detect the proportion of clinic attenders agreeing to ran-
domisation with 95% CIs of 1–2%.
All data was entered into an SPSS database and quantita-
tive findings are expressed as simple proportions of all
clinic attenders, with 95% CI for the principal outcome.
Eligibility criteria for proposed RCT Figure 2
Eligibility criteria for proposed RCT
Women are considered eligible for trial enrolment if they: 
•  Are between 12 and 24 weeks (inclusive) pregnant 
•  Report smoking at least 10 cigarettes daily before pregnancy 
•  Currently smoke at least 5 cigarettes daily 
 
Exclusion criteria 
•  Inability to give informed consent for cognitive reasons 
•  Severe cardiovascular disease 
•  Unstable angina or cardiac arrhythmias 
•  Recent CVA or TIA 
•  Chronic generalised skin disorder or known sensitivity to nicotine patches 
•  Chemical dependence or alcohol addiction problems 
•  Known major fetal anomaly 
 
NB: exclusions not monitored in this pilot BMC Health Services Research 2004, 4:29 http://www.biomedcentral.com/1472-6963/4/29
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Results
Figure 1 shows that 99.3% of women attending for ante-
natal ultrasound imaging during the study period con-
sented to complete a questionnaire. Of questionnaire
respondents, around 27% had smoked in the last week,
but only 163 of these were within the appropriate gesta-
tion range for trial entry. The diagram shows that
although 17% of attenders admitted to smoking on "at
least most days", this number fell to around 13% who
admitted smoking 10 cigarettes daily before they were
pregnant and it fell further to 10% who admitted smoking
both 10 cigarettes daily before pregnancy and 5 currently.
Of these heavier smokers, 5.6% were interested in stop-
ping smoking. Finally, 3.6% [(31) 95%CI, 2.4 to 4.9%] of
women attending for ultrasound both met trial entry cri-
teria as measured on the questionnaire and were inter-
ested in participation in a study involving NRT. RAs
offered study enrolment to 26 of these 31 women and 25
(96%) accepted. The remaining 5 women left the ultra-
sound clinic before RAs could discuss participation with
them. 21 women who agreed to the enrolment offer
attended at least one appointment with the local NHS
smoking cessation in pregnancy advisor.
Perceptions of research and smoking cessation service staff 
involved in pilot
There was consensus amongst RAs and NHS smoking ces-
sation service staff that, if the following problems with
study procedures were remedied, the proportion of
women interested in trial participation who actually
enrolled should increase:
• A number of women were interested in study participa-
tion but did not have sufficient time to discuss this with
the RA in the clinic. These women might have been able
to make time to discuss the study if they had known about
the likelihood of being approached before attending the
ultrasound department.
• On occasions, RAs failed to follow up women who had
expressed an interest in study participation because they
were busy with other duties (e.g. discussing enrolment
with another woman).
• A number of women who had indicated on their ques-
tionnaire that they were interested in participation left the
clinic before the RA could discuss enrolment with them.
The pilot study did not have the resources to contact these
women afterwards.
• Some women reported heavier smoking to smoking ces-
sation advisors than they recorded on questionnaires. This
apparent under-reporting of smoking behaviour may
have resulted in some women who were actually eligible
for study participation, not being offered study
enrolment.
Discussion
We have demonstrated that it is feasible to recruit women
to a trial of NRT in pregnancy as they attend antenatal
ultrasound appointments. Although almost all women
consented to complete a questionnaire enquiring about
their smoking habits, only 10% of these were eligible to
enrol in an RCT and less than 4% appeared likely to par-
ticipate in one.
Our study provides useful, original information for
researchers planning trials of NRT in pregnancy. The two
published trials of NRT use in pregnancy give no informa-
tion about numbers of women were asked to participate
but declined. One trial took two years to enrol 250 preg-
nant women [7] and the other recruited 30 women, but
the time taken to achieve this is not reported [8]. To deter-
mine the level of interest in using NRT amongst pregnant
smokers, Ussher and West conducted a telephone survey
of women who had reported themselves to be smokers
during a "booking" appointment (i.e. their initial antena-
tal appointment) [16]. They found that around one half of
women who admitted to smoking at their antenatal
"booking" appointment (95/177) were interested in
receiving help with stopping smoking, and of those who
admitted to smoking 10 or more cigarettes daily, 56%
were interested in using NRT. This survey, however, was
conducted amongst an ante-natal clinic population with a
smoking prevalence of around 12%, which is much lower
than the national average, so the generalisability of study
findings to other areas is questionable. Additionally, it
gave no indication of the numbers of women who might
agree to randomisation which included the possibility of
being allocated a placebo treatment. Nevertheless, our
findings are not necessarily inconsistent with the London
antenatal clinic survey. We found that approximately 35%
(31/88) of women currently smoking five cigarettes daily
(who also admitted to smoking 10 cigarettes daily before
pregnancy) were interested in trial participation.
Our findings compliment those of Ussher's survey by pro-
viding information about likely participation rates for any
randomised controlled trial. Extrapolating our figure of
3.6% indicates that approximately 36 (95%CI, 24 to 49)
women could be recruited annually to a RCT of NRT in
pregnancy from a maternity hospital with 1000 births/
pregnancies each year. Researchers planning trials of NRT
in pregnancy can use this recruitment rate to inform the
planning of studies. Trialists should note, however, that
we have measured agreement to be randomised rather
than actual randomisation. Additionally, we did not
measure the numbers of exclusions amongst women who
were interested in participation. Figure 2, however, listsBMC Health Services Research 2004, 4:29 http://www.biomedcentral.com/1472-6963/4/29
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Flow Chart of Study Participation Figure 1




















*Proportion of all whom completed questionnaire
Women asked to complete 
Questionnaire, n = 858 
Smoked at all in previous 
Week n = 227 / 851 (26.7%)* 
12-24/40 weeks (inclusive) gestation 
n = 163 / 851 (19.2%)* 
Smoke on most days, n = 146 / 851 
(17.2%)* 
Smoked 10 or more daily before 
Pregnancy, n = 113 / 851 (13.35)* 
Smoke 5 or more daily now, n = 88 / 
851 (10.3%)* 
Interested in stopping smoking 
N = 48 / 851 (5.6%)* 
Interested in participating in 
NRT RCT, n = 31 / 851 (3.6%)* 
Declined, n = 7
Not smoked in previous 
week, n = 624
Not 12 – 24/40 weeks 
gestation, n = 64
Smoke on less than 
most days, n = 17
Smoked <10 before 
pregnancy, n = 33  
Smoke <5 now, n = 25  
No interest in stopping, 
n = 40
No interest in 
participating, n = 17BMC Health Services Research 2004, 4:29 http://www.biomedcentral.com/1472-6963/4/29
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exclusion criteria for a RCT of NRT in pregnancy that the
authors have proposed and consideration of these suggest
that few pregnant women agreeing to enrolment would be
excluded from using NRT on medical grounds. Finally,
pilot study findings are likely to be most applicable to
countries which have policies on the use of NRT in preg-
nancy that are similar to those employed in the UK: the
proportion of women agreeing to randomisation would
probably be lower in any health care system in which
health professionals generally advised pregnant women
against using NRT.
Some modifications to the recruitment method we used
might be needed to maximise trial recruitment rates.
Recruitment from antenatal ultrasound waiting areas
might be increased if women were sent information about
the likelihood of being approached to join any trial before
they attended (e.g. sending information out with appoint-
ments). Additionally, providing enough resources to
ensure that a member of trial staff is always present to ask
patients to join a trial is important. This would overcome
the problem of missing potentially interested women
when the researcher responsible for recruiting is busy
enrolling other potential participants. Any recruitment
method should also allow for the fact that some women
who are interested in participating will not be able to wait
in the clinic to discuss this further. Recruitment would,
therefore, be enhanced if enough resources were provided
to allow research staff to make contact with these women
later, visiting them at home if necessary.
The observation by smoking cessation service staff that
some women admitted smoking more heavily to them
than they admitted on questionnaires is consistent with
the literature. Aveyard investigated the relationship
between urinary cotinine levels and reported numbers of
cigarettes smoked during pregnancy and concluded that,
at booking, some pregnant women probably minimise
the numbers of cigarettes that they report smoking [17].
Similarly, Owen and McNeil's investigation of salivary
cotinine levels in pregnancy indicated that a small
number of pregnant women actually conceal the fact that
they smoke [18]. These research findings probably reflect
the fact that, in the UK, there is a social stigma attached to
smoking in pregnancy which is likely to bias question-
naire respondents against an honest disclosure of their
smoking habit. Some women in our pilot may have been
happier to disclose the full extent of their smoking to a
supportive health professional than they were to a ques-
tionnaire distributed by a RA in an out patient waiting
area.
Trialists could reduce the impact that under-reporting of
heaviness of smoking might have on trial recruitment by
avoiding the use of questionnaires to quantify smoking
habits. Questionnaires used in recruitment to trials of
NRT in pregnancy might be more effective if they merely
ask women to disclose whether or not they smoke and if
they are interested in using NRT to stop. All who smoke
and wish to stop using NRT could then be invited for fur-
ther discussion of trial entry with a researcher or health
professional and during this disclosure a more accurate
assessment of heaviness of smoking might be obtained.
Conclusions
We have demonstrated that it is feasible to recruit preg-
nant women to a trial of nicotine replacement therapy in
pregnancy in the antenatal ultrasound clinics. Using sim-
ilar recruitment methods between 24 and 49 pregnant
women per 1000 approached are likely to consent to par-
ticipation in an RCT. RCT(s) of NRT in pregnancy are
required and this data will help researchers planning such
trials to determine the resources required to answer
important questions concerning the effectiveness and
safety of NRT in pregnancy.
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